Last time you’ll see this

You are receiving this message because you opted in to receive information about our upcoming campaigns from InvestorPlace. If you don’t want to receive messages about this campaign in the future you can unsubscribe here but you will no longer receive reminders and supporting content for this campaign.   Dear Reader, FDA approval for a breakthrough drug is one of the biggest wealth-creation events in the stock market. I’ve been tracking a tiny, $7 million firm that’s currently in Phase 3 trials and could be on the verge of receiving final government approval. This new treatment could result in a new leader in one of the biggest drug markets of all time while minting a new batch of millionaires for those who invested early. But today is your final chance to receive my full analysis on this special situation, including more than $14,000 worth of bonuses that come with it. This includes an entire FREE bonus year to my elite high-growth technology research advisory. If you’d like to secure yours, all you have to do is sign up by midnight tonight. There’s less than 8 hours left until this special opportunity expires. If you want all the details on one of the biggest breakthroughs in five decades… including my exact plan on how to profit from it… don’t delay — discover the details now by watching my presentation here. Sincerely, Matt McCall Editor, Early Stage Investor   MANAGE YOUR INVESTORPLACE ACCOUNT: We hope this timely investing advice is valuable to you. As you know the markets move fast and conditions change frequently. So please check the current issue for the most recent advice. To make sure you received the most recent updates, please tell us if your email has changed by visiting here: https://investorplace.com/ipi/e/ Click here to unsubscribe. InvestorPlace Media, LLC. 9201 Corporate Blvd, Suite 200 Rockville, MD 20850 If you have any questions call 1-800-219-8592. Copyright © 2019 InvestorPlace Media, LLC. All rights reserved. ————————————————————————————————- Please note that we cannot be liable for any missed bulletins caused by overzealous spam filters. To ensure that you continue to receive this valuable part of your service please take a moment to add (MattMcCall@exct.Investorplace.com) to your address book. Click here for instructions: http://www.investorplace.com/whitelist.html?eml=MattMcCall@exct.Investorplace.com